Abbott Laboratories (ABT): insider & executive buying
Abbott Laboratories · Health Care · ref. ETF XLV · price $111.59
In short — 3 insiders bought Abbott Laboratories over ~6 months (3 buys, total $1.3M, latest May 7, 26) — cluster buy. Public Form 4 data, informative (not a performance signal).
Are Abbott Laboratories's executives buying their own shares? Here are the disclosed insider buys over the last 6 months — a transparency data point, not an outperformance signal.
📈 1-year price
$111.59-15.1% over range
Aug 28, 25low $82.56 · high $136.62Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 17 analysts
Latest insider buys on Abbott Laboratories
| Date | Insider | Role | Shares | Amount |
|---|---|---|---|---|
| May 7, 26 | Stratton John G | Dir | 2,000 | $174k |
| Apr 27, 26 | Starks Daniel J | Dir | 10,000 | $927k |
| Apr 23, 26 | Boudreau Philip P | EVP, CFO | 2,200 | $201k |
⚠️ Open-market buys reported to the SEC (Form 4). Transparency data, not advice nor an outperformance signal (our backtests show no reliable edge).
Frequently asked questions
Have Abbott Laboratories's executives bought shares recently?
3 Abbott Laboratories insider(s) bought $1.3M over ~6 months (latest May 7, 26). A buy shows confidence, but our backtests show no performance edge.
Is insider buying a good signal for ABT?
It's useful transparency data, but NOT a performance guarantee: our historical tests show no reliable edge from following insider buys. Cross-check with fundamentals and analyst views.
Where does this data come from?
From Form 4 filings with the SEC (mandatory for officers and 10%+ holders), aggregated and refreshed regularly.
💬 A question about Abbott Laboratories? The JPI assistant answers using our backtest data.